Jump to content


Replying to LRP4: A new bone anabolic drug target?


Post Options

  • This post will need approval from a moderator before this post is shown.
  or Cancel


Topic Summary

Dr. Joseph Lorenzo

Posted 06 January 2015 - 12:45 PM

Most available therapies for osteoporosis function as inhibitors of bone resorption. However, in patients with very low bone mass or those who already have a fragility fracture, anabolic therapies, which enhance bone formation, may be more effective (1). Currently, only analogs of parathyroid hormone are approved as bone anabolic agents to treat osteoporosis. The discovery that the canonical Wnt beta-catenin signaling pathway stimulates bone formation has identified a number of new drug targets, which may be exploited to develop novel anabolic therapies for osteoporosis (2). Wnts are signaling proteins that are produced in the bone microenvironment. They bind specific receptor complexes on osteoblast lineage cells and enhance the deve...

Review the complete topic (launches new window)